A Phase II Study of 3′-Deoxy-3′-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688
暂无分享,去创建一个
Fenghai Duan | Mark Muzi | Linda Hovanessian-Larsen | David A Mankoff | John P Muzi | John P. Muzi | Jean B. Cormack | Lale Kostakoglu | Daniel A Pryma | D. Mankoff | P. Jolles | A. Shields | H. Bear | M. Muzi | L. Kostakoglu | F. Duan | L. Hovanessian-Larsen | D. Pryma | Jean Cormack | J. Specht | Jennifer M Specht | Harry D Bear | M. Idowu | Anthony F Shields | Michael O Idowu | Paul R Jolles | John Miliziano | Sharon Mallett | J. Miliziano | S. Mallett | Linda Hovanessian-Larsen
[1] S. Shousha,et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. , 2005, Cancer research.
[2] J. Bading,et al. Imaging of Cell Proliferation: Status and Prospects , 2008, Journal of Nuclear Medicine.
[3] M. Brennan,et al. Locally advanced and inflammatory breast cancer. , 2005, Australian family physician.
[4] J. Olson,et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S Detre,et al. Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer , 2014, British Journal of Cancer.
[6] J. Martí-Climent,et al. [¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: usefulness of different quantitative methods of tumor proliferation. , 2014, Revista espanola de medicina nuclear e imagen molecular.
[7] M. Hatt,et al. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. , 2014, European journal of cancer.
[8] Eric O. Aboagye,et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[9] Winfried Brenner,et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Jacob,et al. Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3´-deoxy-3´-fluorothymidine PET: a pilot study. , 2012, Biomarkers in medicine.
[11] P. Fumoleau,et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[12] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.
[13] J. Bonneterre,et al. Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG–PET after the first course , 2011, Breast Cancer Research and Treatment.
[14] J. Bergh,et al. A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. , 2007, European journal of cancer.
[15] Z. Chang,et al. Differential phosphorylation of human thymidine kinase in proliferating and M phase-arrested human cells. , 1994, The Journal of biological chemistry.
[16] E. Perez,et al. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Joel S. Karp,et al. Qualification of PET Scanners for Use in Multicenter Cancer Clinical Trials: The American College of Radiology Imaging Network Experience , 2009, Journal of Nuclear Medicine.
[18] A. Bianco,et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Hatt,et al. Comparison Between 18F-FDG PET Image–Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer , 2013, The Journal of Nuclear Medicine.
[20] R. Thomas,et al. Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study , 2006, British Journal of Cancer.
[21] B. Munch‐Petersen,et al. Human thymidine kinase 1. Regulation in normal and malignant cells. , 1995, Advances in enzyme regulation.
[22] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[23] Federico Turkheimer,et al. [18F]-3′Deoxy-3′-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel , 2011, Clinical Cancer Research.
[24] Michael E. Phelps,et al. Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2005, Molecular Imaging and Biology.
[25] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Jacob Cohen,et al. Applied multiple regression/correlation analysis for the behavioral sciences , 1979 .
[27] F. Turkheimer,et al. Kinetic filtering of [18F]Fluorothymidine in positron emission tomography studies , 2010, Physics in medicine and biology.
[28] P. Marsden,et al. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. , 2012, European journal of cancer.
[29] M. Sormani,et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] F E Turkheimer,et al. Quantification of intra-tumour cell proliferation heterogeneity using imaging descriptors of 18F fluorothymidine-positron emission tomography , 2013, Physics in medicine and biology.
[31] Ludovic Ferrer,et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Irene L Andrulis,et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. , 2006, The New England journal of medicine.
[33] Otto Muzik,et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.
[34] Christian Ingvar,et al. Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies , 2011, BMC Cancer.
[35] J. Christensen,et al. [18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells , 2011, Clinical Cancer Research.
[36] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[37] Jack Cuzick,et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.